WeVote
Log In

Bill

Bill

A 1428

Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug

2025 Regular Session Introduced by Phara Souffrant Forrest and 1 co-sponsor

Bill A 1428 requires insurers to cover brand name drugs when the FDA declares a supply issue with generics, ensuring patients maintain access to necessary medications.

ADVANCED TO THIRD READING CAL.311
0
WeVote Research Nonpartisan
Bill Summary · A 1428

Summary of Bill A 1428

Bill Information

  • Bill Number: A 1428
  • Title: Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug
  • Status: Referred to Insurance
  • Introduced: January 09, 2025
  • Classification: Bill

Purpose and Intent

Bill A 1428 aims to ensure that patients have access to necessary medications when generic drugs are unavailable due to supply issues. By mandating that insurers cover the substitution of brand name drugs in these circumstances, the bill seeks to alleviate potential gaps in medication access for patients who rely on these prescriptions.

Key Provisions

  • Insurance Coverage Requirement: The bill requires health insurers to provide coverage for brand name prescription drugs when the FDA has officially declared a supply issue with the corresponding generic version.
  • Definition of Supply Issue: The bill does not specify the criteria for a "supply issue," but it is understood to align with FDA determinations regarding shortages of generic medications.
  • Patient Access: This provision is designed to ensure that patients can continue their treatment regimens without interruption, even when generic alternatives are not available.

Who Would Be Affected

  • Patients: Individuals who rely on prescription medications, particularly those who may be affected by shortages of generic drugs, will benefit from this legislation.
  • Health Insurers: Insurance companies will need to adjust their policies and coverage plans to comply with the new requirement, potentially impacting their cost structures.
  • Pharmaceutical Companies: Manufacturers of brand name drugs may see an increase in demand during periods when generics are unavailable.

Procedural Aspects

  • Current Status: As of January 09, 2025, the bill has been referred to the Insurance Committee for further consideration.
  • Related Legislation: This bill is related to A 10185 from the prior session, which may provide context or background on similar legislative efforts.

Conclusion

Bill A 1428 represents a proactive approach to addressing medication access issues stemming from generic drug shortages. By mandating insurance coverage for brand name alternatives, the bill aims to protect patients' health and ensure continuity of care during supply disruptions. As it progresses through the legislative process, stakeholders in the healthcare and insurance sectors will need to prepare for its potential implications.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.